OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research note issued on Monday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Price Performance

OpGen stock opened at $1.54 on Monday. OpGen has a fifty-two week low of $1.40 and a fifty-two week high of $9.90. The stock’s fifty day moving average is $1.81 and its two-hundred day moving average is $2.40.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.